BACKGROUND: Traditionally, single-unit red blood cell transfusions were believed to be insufficient to treat anemia, but recent data suggest that they may lead to a safe reduction of transfusion requirements. We tested this hypothesis by changing from a double- to a single-unit red blood cell transfusion policy. DESIGN AND METHODS: We performed a retrospective cohort study in patients with hematologic malignancies receiving intensive chemotherapy or hematopoietic stem cell transplantation. The major end-points were the reduction in the total number of red blood cell units per therapy cycle and per day of aplasia. The study comprised 139 patients who received 272 therapy cycles. Overall 2212 red blood cell units were administered in 1548 transfusions. RESULTS: During the periods of the double- and single-unit policies, one red blood cell unit was transfused in 25% and 84% of the cases and the median number of red blood cell units per transfusion was two and one, respectively. Single-unit transfusion led to a 25% reduction of red blood cell usage per therapy cycle and 24% per aplasia day, but was not associated with a higher out-patient transfusion frequency. In multivariate analysis, single-unit transfusion resulted in a reduction of 2.7 red blood cell units per treatment cycle (P = 0.001). The pre-transfusion hemoglobin levels were lower during the single-unit period (median 61 g/L versus 64 g/L) and more transfusions were administered to patients with hemoglobin values of 60 gl/L or less (47% versus 26%). There was no evidence of more severe bleeding or more platelet transfusions during the single-unit period and the overall survival was similar in both cohorts. CONCLUSIONS: Implementing a single-unit transfusion policy saves 25% of red blood cell units and, thereby, reduces the risks associated with allogeneic blood transfusions.
BACKGROUND: Traditionally, single-unit red blood cell transfusions were believed to be insufficient to treat anemia, but recent data suggest that they may lead to a safe reduction of transfusion requirements. We tested this hypothesis by changing from a double- to a single-unit red blood cell transfusion policy. DESIGN AND METHODS: We performed a retrospective cohort study in patients with hematologic malignancies receiving intensive chemotherapy or hematopoietic stem cell transplantation. The major end-points were the reduction in the total number of red blood cell units per therapy cycle and per day of aplasia. The study comprised 139 patients who received 272 therapy cycles. Overall 2212 red blood cell units were administered in 1548 transfusions. RESULTS: During the periods of the double- and single-unit policies, one red blood cell unit was transfused in 25% and 84% of the cases and the median number of red blood cell units per transfusion was two and one, respectively. Single-unit transfusion led to a 25% reduction of red blood cell usage per therapy cycle and 24% per aplasia day, but was not associated with a higher out-patient transfusion frequency. In multivariate analysis, single-unit transfusion resulted in a reduction of 2.7 red blood cell units per treatment cycle (P = 0.001). The pre-transfusion hemoglobin levels were lower during the single-unit period (median 61 g/L versus 64 g/L) and more transfusions were administered to patients with hemoglobin values of 60 gl/L or less (47% versus 26%). There was no evidence of more severe bleeding or more platelet transfusions during the single-unit period and the overall survival was similar in both cohorts. CONCLUSIONS: Implementing a single-unit transfusion policy saves 25% of red blood cell units and, thereby, reduces the risks associated with allogeneic blood transfusions.
Authors: Jeffrey L Carson; Michael L Terrin; Jay Magaziner; Bernard R Chaitman; Fred S Apple; David A Heck; David Sanders Journal: Transfusion Date: 2006-12 Impact factor: 3.157
Authors: Aryeh Shander; Axel Hofmann; Sherri Ozawa; Oliver M Theusinger; Hans Gombotz; Donat R Spahn Journal: Transfusion Date: 2009-12-09 Impact factor: 3.157
Authors: Matthew A Warner; Nilesh S Jambhekar; Salwa Saadeh; Eapen K Jacob; Justin D Kreuter; William C Mundell; Alberto Marquez; Andrew A Higgins; Nageswar R Madde; William J Hogan; Daryl J Kor Journal: Transfusion Date: 2019-06-20 Impact factor: 3.157
Authors: Lise J Estcourt; Reem Malouf; Marialena Trivella; Dean A Fergusson; Sally Hopewell; Michael F Murphy Journal: Cochrane Database Syst Rev Date: 2017-01-27
Authors: Andrea Tendas; Pasquale Niscola; Luca Cupelli; Laura Scaramucci; Marco Giovannini; Paolo de Fabritiis Journal: Haematologica Date: 2012-07 Impact factor: 9.941
Authors: Richard Warwick; Neeraj Mediratta; John Chalmers; Mark Pullan; Matthew Shaw; James McShane; Michael Poullis Journal: Interact Cardiovasc Thorac Surg Date: 2013-02-28
Authors: Evan M Bloch; Charlotte Ingram; Jennifer Hull; Susan Fawcus; John Anthony; Randolph Green-Thompson; Robert L Crookes; Solomuzi Ngcobo; Darryl V Creel; Lauren Courtney; Greg R M Bellairs; Edward L Murphy Journal: Transfusion Date: 2018-07-10 Impact factor: 3.157
Authors: Marie E Steiner; Nicole D Zantek; Simon J Stanworth; Robert I Parker; Stacey L Valentine; Leslie E Lehmann; Cassandra D Josephson; Scot T Bateman; Naomi L C Luban Journal: Pediatr Crit Care Med Date: 2018-09 Impact factor: 3.624